Cme (CME) Research & Development (2009 - 2026)

Cme (CME) has reported Research & Development for 18 consecutive years, with $83.3 million the latest figure, recorded in Q2 2026.

• Quarterly Research & Development rose 17.49% year-over-year to $83.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $306.5 million (up 13.98% YoY) and the FY2025 annual result came in at $283.2 million, up 10.71% from the prior year.
• Research & Development improved to $83.3 million in Q2 2026 per CME's latest filing, from $76.6 million in the prior quarter.
• Over the last five years, Research & Development for CME reached as high as $83.3 million in Q2 2026 and fell as low as $45.9 million in Q1 2022.
• A 5-year average of $61.5 million and a median of $61.8 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development declined 6.9% — and 2024, when it rose 20.26%.
• Year by year, Research & Development stood at $50.0 million in 2022, then increased by 17.0% to $58.5 million in 2023, then advanced by 12.31% to $65.7 million in 2024, then gained by 14.46% to $75.2 million in 2025, then advanced by 10.77% to $83.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $83.3 million, $76.6 million, and $75.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.